BioSpace News Archive

Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) today announced that it has recently received the written meeting minutes from a June Type C meeting held with the U.S. Food and Drug Administration (“FDA”) regarding RAD011, a synthetic cannabidiol oral solution.

Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that new Brilacidin antiviral data, based on research conducted by George Mason University (GMU)/National Center for Biodefense and Infectious Diseases researchers, was presented yesterday, July 21, 2021, at the American Society of Virology’s 40th Annual Meeting (ASV 2021).

Moderna, Inc. today announced a new supply agreement with Taiwan for 20 million doses of Moderna’s COVID-19 vaccine and its updated variant booster vaccine candidate, if authorized, to begin delivery in 2022 and an additional 15 million doses in 2023.

TAE Life Sciences (TLS), a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced that as part of its growing pipeline of investigational therapies, it has identified several proprietary drug candidates, including TC220 and TC221.

Humanigen, Inc. have received approval from South Korea’s MFDS (the South Korean equivalent of the U.S. FDA) to conduct a Phase 1 clinical study of lenzilumab, which may support potential use in the treatment of hospitalized COVID-19 patients.

The pulmonary devices market was valued at US$ 18,598.56 million in 2019 and is projected to reach US$ 39,965.01 million by 2027; it is expected to grow at a CAGR of 10.1%from 2020 to 2027.

The “Global Health Supplements Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis.

This follows the promising results from initial tests with metal conjugated antibodies against E. coli.

Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today the publication of a post-hoc analysis of its successful Phase 2b knee osteoarthritis clinical trial in Rheumatology and Therapy.

In total, 264 individuals were enrolled in the study with duration of symptoms that ranged from one (1) day to more than 10 days.